ginkgo biloba extract + poly-L-lysine + solid lipid nanoparticles

This research-stage nano-delivery system consists of solid lipid nanoparticles (SLNPs) formulated with sphingomyelin and cholesterol, incorporating Ginkgo biloba leaf extract (GBE) and functionalized with poly-L-lysine (PLL). It is designed as a gene therapy platform for the delivery of small interfering RNA (siRNA) to treat neurodegenerative disorders, specifically Parkinson's disease. The Ginkgo biloba extract component provides neuroprotection and facilitates blood-brain barrier (BBB) crossing by activating A1 adenosine receptors, while the poly-L-lysine enables the electrostatic binding and protection of the siRNA payload from nuclease degradation. In vitro studies using human neuroblastoma (SH-SY5Y) and embryonic kidney (HEK293) cells have demonstrated the system's biocompatibility, low toxicity, and effectiveness in delivering therapeutics while maintaining high cellular viability.